EGFR and non-small cell lung carcinoma: Therefore, when the status of EGFR mutations cannot be tested in a timely manner because of inadequate tumor tissue or when treatment for NSCLC is urgent for clinical reasons, the IHC staining result of TTF-1 may be used to guide systemic anticancer therapy.